As shares tank, Orchard once again restructures, shedding gene therapy programs and a large part of the staff
Almost exactly 2 years ago, Orchard Therapeutics execs reorganized the pipeline, shed staff and circled their wagons around what they considered the most vital part of its R&D effort. Today, they’re going back in to cut again, taking out once key programs while designating a new lineup as essential to its future.
Orchard, a UK/US hybrid gene therapy company, is taking the ax to therapies for rare primary immune deficiencies. These include: OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease and Strimvelis, a gammaretroviral vector-based gene therapy approved in Europe for adenosine deaminase severe combined immunodeficiency (ADA-SCID).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.